The rise of ultra-processed foods (UPFs) in human diets is harming global public health. However, policy responses are still emerging-much like tobacco control efforts decades ago-indicating the need to understand root causes and accelerate global action. This paper, the third in a three-part Lancet Series, takes several steps to advance knowledge of these causes, and to inform a global public health response. First, we show that the UPF industry is a key driver of the problem, as its leading corporations and co-dependent actors have expanded and restructured food systems almost everywhere, in favour of ultra-processed diets. The higher profitability of UPFs compared with other types of food fuels this growth, by financially incentivising the ultra-processed business model over alternatives, and generating resources for continued expansion. Second, we highlight that the main barrier to advancing policy responses is the industry's corporate political activities, coordinated transnationally through a global network of front groups, multi-stakeholder initiatives, and research partners, to counter opposition and block regulation. These activities include direct lobbying, infiltrating government agencies, and litigation; promoting corporate-friendly governance models, forms of regulation, and civil societies; and framing debate, generating favourable evidence, and manufacturing scientific doubt. Third, we present strategies for reducing the UPF industry's power in food systems and for mobilising a global public health response. Reducing the UPF industry's power involves disrupting the ultra-processed business model and redistributing resources to other types of food producers; protecting food governance from corporate interference; and implementing robust conflict of interest safeguards in policy making, research, and professional practice. Mobilising a global response includes framing UPFs as a priority global health issue; building powerful global and country-level advocacy coalitions; generating legal, research, and communication capacities to empower advocacy and drive policy change; and ensuring a just transition to low-UPF diets. A coordinated, well resourced global response is essential-one that confronts corporate power, reclaims public policy space, and restructures food systems to prioritise health, equity, and sustainability over corporate profit.

Transcatheter devices designed for calcific aortic stenosis are not optimised for use in native aortic regurgitation, and data on aortic regurgitation-dedicated platforms are limited. The extended ALIGN-AR pivotal experience with a prospectively enrolled continued-access cohort and longer follow-up aimed to characterise the safety, valve function, and clinical outcomes of transcatheter aortic valve intervention (TAVI) with a dedicated device in aortic regurgitation.

First discovered in 1999 in Malaysia, Nipah virus (NiV) causes yearly outbreaks throughout south and southeast Asia with associated mortality rates of 40-75%. Due to the structural and sequence similarities between the NiV and Hendra virus (HeV) attachment G glycoproteins, and the extensive extant evidence of the ability of a recombinant soluble glycoprotein G (HeV-sG) to provide heterologous cross-protective immunity when used as vaccine (HeV-sG-V), this study aimed to evaluate HeV-sG-V for safety, tolerability, and immunogenicity against NiV.

Acute kidney injury (AKI) is a common and important complication of major surgery, yet recommended preventive care is rarely administered. We used urinary biomarkers to identify patients at high risk of AKI and implemented a preventive care strategy to reduce AKI within 72 h after major surgery.

Hyperemesis gravidarum describes nausea and vomiting in pregnancy severe enough to cause weight loss, dehydration, electrolyte imbalance, and nutritional deficiencies. The condition can render women so physically and mentally unwell that they are at increased risk of terminating a wanted pregnancy and experiencing suicidal ideation. Concerns regarding prescribing in pregnancy and inaccurate assumptions that the condition is self-limiting result in women being dismissed and having difficulty accessing appropriate care. Over the past decade, a wealth of literature has been published that gives new insights into the causes of hyperemesis gravidarum, the safety of antiemetic therapy, and short-term and long-term consequences for women with the condition and their children. This Review summarises the findings of this literature with the aim of informing decisions about the care of these women and future research priorities.